Activating transcription factor-2 (ATF2) is a key determinant of resistance to endocrine treatment in an in vitro model of breast cancer

BACKGROUND: Activating transcription factor-2 (ATF2), a member of the leucine zipper family of DNA binding proteins, has been implicated as a tumour suppressor in breast cancer. However, its exact role in breast cancer endocrine resistance is still unclear. We have previously shown that silencing of...

Descripción completa

Detalles Bibliográficos
Autores principales: Giannoudis, Athina, Malki, Mohammed Imad, Rudraraju, Bharath, Mohhamed, Hisham, Menon, Suraj, Liloglou, Triantafillos, Ali, Simak, Carroll, Jason S., Palmieri, Carlo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7667764/
https://www.ncbi.nlm.nih.gov/pubmed/33198803
http://dx.doi.org/10.1186/s13058-020-01359-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7667764/
https://www.ncbi.nlm.nih.gov/pubmed/33198803
http://dx.doi.org/10.1186/s13058-020-01359-7

Ejemplares similares